Date:10/19/2010

nnual report on Form 10-K for the year ended December 31, 2009 and quarterly and current reports on Form 10-Q and 8-K. These forward-looking statements reflect Cardiac Science Corporation's expectations as of the date of this document. Cardiac Science Corporation undertakes no obligation to update the information provided herein.

Contact Information:Cardiac Science Contact: Investor Contact:Media Contact:Investor Relations

Cardiac Science Corporation

425.402.2009Matt Clawson

Allen & Caron

949.474.4300

matt@allencaron.comChristopher Gale

EVC Group Inc.

646.201.5431

203.570.4681

cgale@evcgroup.comOpto Circuits Contact:IR: ir@optoindia.com

Media: media@optoindia.com

T: +91 80 2852 1040/41/42(Logo: http://photos.prnewswire.com/prnh/20080306/AQTH510LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

'/>"/>

SOURCE Cardiac Science Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Hanger Orthopedic Group Signs Definitive Merger Agreement To Acquire Accelerated Care Plus
2. Roche Acquires RALS IT Connectivity Assets to Strengthen Presence in Point-of-Care Information Management
3. WPI Holdings Acquires Wilmington Medical Supply Inc.
4. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
5. Pioneer® Surgical Technology, Inc. Announces Agreement to Acquire Exclusive Access to the Cequence™ Cervical Plate System From SpineSmith, LP
6. Thompson Group Acquires Hamilton Sundstrands Applied Instrument Technologies
7. Omnicell Acquires Pandora Data Systems
8. RoundTable Healthcare Partners Portfolio Company, Argon Medical Devices, Inc., Acquires Critical Care and Extended Dwell Catheter Product Platforms From BD
9. Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash
10. New American Therapeutics Acquires Antiviral Drug Denavir®
11. Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion